Biopharmaceutical company BerGenBio ASA (OSE:BGBIO) announced on Tuesday a collaboration with precision medicine company Tempus AI Inc (NASDAQ:TEM) to accelerate the development of its selective AXL kinase inhibitor, bemcentinib, in first-line non-small cell lung cancer (NSCLC) patients with STK11 mutations.

This partnership will provide BerGenBio access to Tempus' real-world clinical and molecular data to enhance its ongoing Phase 1b/2a BGBC016 trial. Tempus' AI-enabled platform will provide insights into the genomic landscape and treatment responses of NSCLC patients with STK11 mutations.

Upon completion of the BGBC016 study, the companies plan to present insights derived from the resulting data to regulatory agencies.